278 related articles for article (PubMed ID: 12209649)
1. CpG-DNA aided cross-presentation of soluble antigens by dendritic cells.
Maurer T; Heit A; Hochrein H; Ampenberger F; O'Keeffe M; Bauer S; Lipford GB; Vabulas RM; Wagner H
Eur J Immunol; 2002 Aug; 32(8):2356-64. PubMed ID: 12209649
[TBL] [Abstract][Full Text] [Related]
2. CpG oligodeoxynucleotides enhance FcgammaRI-mediated cross presentation by dendritic cells.
Bevaart L; Van Ojik HH; Sun AW; Sulahian TH; Leusen JH; Weiner GJ; Van De Winkel JG; Van Vugt MJ
Int Immunol; 2004 Aug; 16(8):1091-8. PubMed ID: 15192052
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC.
Maecker HT; Umetsu DT; DeKruyff RH; Levy S
J Immunol; 1998 Dec; 161(12):6532-6. PubMed ID: 9862678
[TBL] [Abstract][Full Text] [Related]
4. The synthetic TLR2 agonist BPPcysMPEG leads to efficient cross-priming against co-administered and linked antigens.
Prajeeth CK; Jirmo AC; Krishnaswamy JK; Ebensen T; Guzman CA; Weiss S; Constabel H; Schmidt RE; Behrens GM
Eur J Immunol; 2010 May; 40(5):1272-83. PubMed ID: 20213735
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells.
Sun JB; Eriksson K; Li BL; Lindblad M; Azem J; Holmgren J
Clin Immunol; 2004 Jul; 112(1):35-44. PubMed ID: 15207780
[TBL] [Abstract][Full Text] [Related]
6. Heat shock protein-antigen fusions lose their enhanced immunostimulatory capacity after endotoxin depletion.
Marincek BC; Kühnle MC; Srokowski C; Schild H; Hämmerling G; Momburg F
Mol Immunol; 2008 Nov; 46(1):181-91. PubMed ID: 18804283
[TBL] [Abstract][Full Text] [Related]
7. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA.
Jakob T; Walker PS; Krieg AM; Udey MC; Vogel JC
J Immunol; 1998 Sep; 161(6):3042-9. PubMed ID: 9743369
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway.
Rock KL; Clark K
J Immunol; 1996 May; 156(10):3721-6. PubMed ID: 8621907
[TBL] [Abstract][Full Text] [Related]
9. CpG oligodeoxynucleotides down-regulate macrophage class II MHC antigen processing.
Chu RS; Askew D; Noss EH; Tobian A; Krieg AM; Harding CV
J Immunol; 1999 Aug; 163(3):1188-94. PubMed ID: 10415013
[TBL] [Abstract][Full Text] [Related]
10. Adenosine, through the A1 receptor, inhibits vesicular MHC class I cross-presentation by resting DC.
Chen L; Fredholm BB; Jondal M
Mol Immunol; 2008 Apr; 45(8):2247-54. PubMed ID: 18178251
[TBL] [Abstract][Full Text] [Related]
11. CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses.
Vabulas RM; Pircher H; Lipford GB; Häcker H; Wagner H
J Immunol; 2000 Mar; 164(5):2372-8. PubMed ID: 10679072
[TBL] [Abstract][Full Text] [Related]
12. Coupling of antigen to cholera toxin for dendritic cell vaccination promotes the induction of MHC class I-restricted cytotoxic T cells and the rejection of a cognate antigen-expressing model tumor.
Eriksson K; Sun JB; Nordström I; Fredriksson M; Lindblad M; Li BL; Holmgren J
Eur J Immunol; 2004 May; 34(5):1272-81. PubMed ID: 15114660
[TBL] [Abstract][Full Text] [Related]
13. Impaired lung dendritic cell migration and T cell stimulation induced by immunostimulatory oligonucleotides contribute to reduced allergic airway inflammation.
Constabel H; Stankov MV; Hartwig C; Tschernig T; Behrens GM
J Immunol; 2009 Sep; 183(5):3443-53. PubMed ID: 19667097
[TBL] [Abstract][Full Text] [Related]
14. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
15. CpG-DNA aided cross-priming by cross-presenting B cells.
Heit A; Huster KM; Schmitz F; Schiemann M; Busch DH; Wagner H
J Immunol; 2004 Feb; 172(3):1501-7. PubMed ID: 14734727
[TBL] [Abstract][Full Text] [Related]
16. Topical TLR9 agonists induce more efficient cross-presentation of injected protein antigen than parenteral TLR9 agonists do.
Najar HM; Dutz JP
Eur J Immunol; 2007 Aug; 37(8):2242-56. PubMed ID: 17634951
[TBL] [Abstract][Full Text] [Related]
17. Enhanced CTL response by controlled intracellular trafficking of antigen in dendritic cells following DNA vaccination.
Isaji K; Kawase A; Matono M; Guan X; Nishikawa M; Takakura Y
J Control Release; 2009 May; 135(3):227-33. PubMed ID: 19331843
[TBL] [Abstract][Full Text] [Related]
18. Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses.
Newman MJ; Wu JY; Gardner BH; Munroe KJ; Leombruno D; Recchia J; Kensil CR; Coughlin RT
J Immunol; 1992 Apr; 148(8):2357-62. PubMed ID: 1373166
[TBL] [Abstract][Full Text] [Related]
19. Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides.
Nair S; Wearsch PA; Mitchell DA; Wassenberg JJ; Gilboa E; Nicchitta CV
J Immunol; 1999 Jun; 162(11):6426-32. PubMed ID: 10352256
[TBL] [Abstract][Full Text] [Related]
20. APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells.
Warren TL; Bhatia SK; Acosta AM; Dahle CE; Ratliff TL; Krieg AM; Weiner GJ
J Immunol; 2000 Dec; 165(11):6244-51. PubMed ID: 11086059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]